Manufacturer Pharmaceutical Riociguat 99% Riociguat

• Customization: Available
• CAS No.: 625115-55-1
• Formula: C20h19fn8o2
• Model NO.: QS-Riociguat
• EINECS: 641-755-1
• Packaging Material: Negotiable
• Storage Method: Normal
• Shelf Life: >12 Months
• Nutrient Composition: Riociguat
• Resource: Riociguat
• The content of active substances: >99%
• Product Name: Riociguat
• Name: Riociguat Powder
• Appearance: White Powder
• Colour: White
• Grade: Veterinary Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Density: 1.51
• Boiling Point: 567.202c
• Mf: C20h19fn8o2
• MW: 422.42
• Flash Point: 296.8c
• Pka: 1.51
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Riociguat
• Origin: Xi`an
• Production Capacity: 1000kg/Month

Product Description

Manufacturer Pharmaceutical Riociguat 99% Riociguat

Product Description

Product Details

Product Name	Riociguat
Appearance	Riociguat Powder
Assay	>99%
MW	422.42
MF	C20H19FN8O2
Density	1.51
pKa	1.51

Riociguat is a soluble guanylate cyclase (sGC) stimulator, targeting an enzyme in the cardiopulmonary system that serves as a receptor for nitric oxide (NO). When NO binds to sGC, it triggers the production of cyclic GMP (cGMP), a signaling molecule crucial for regulating vascular tone, cell proliferation, fibrosis, and inflammation. Pulmonary hypertension is linked to endothelial dysfunction, reduced NO synthesis, and insufficient activation of the NO-sGC-cGMP pathway. Riociguat operates through a dual mechanism: it enhances sGC sensitivity to endogenous NO by stabilizing NO-sGC binding and directly stimulates sGC independently of NO via a separate binding site. By activating the NO-sGC-cGMP pathway, riociguat increases cGMP levels, promoting vasodilation and improving vascular function.

Application&Function

The compound corresponding to Cas 625115-55-1 is **Riociguat**, a stimulator of soluble guanylate cyclase (sGC), primarily used to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat works by enhancing the sensitivity of sGC to nitric oxide (NO) and directly stimulating sGC, increasing intracellular cyclic guanosine monophosphate (cGMP) levels, thereby relaxing vascular smooth muscle, reducing pulmonary artery pressure, and improving blood flow. It is administered orally in tablet form, with dosages adjusted based on individual patient needs. Common side effects include hypotension, and it is contraindicated in pregnant women due to its teratogenic effects. Riociguat provides an effective treatment option for patients with pulmonary hypertension, significantly improving quality of life and prognosis.

Specification